Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track MEDP with free AI briefings, catalyst countdowns, and dilution alerts.

MEDP · Medpace Holdings, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$705.3M Cash on Hand
CF+ Cash Runway
Follow MEDP by email Get an email when MEDP reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about MEDP, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Invimestrocel Ischemic Stroke Phase 3 · NCT03545607 Terminated
Lerodalcibep Familial Hypercholesterolemia - Heterozygous Phase 3 · NCT07102511 Enrolling by invitation
TNX-103 Pulmonary Hypertension Phase 3 · NCT05983250 Active not recruiting
Investigator's choice HSV Infection Phase 3 · NCT03073967 Completed
Etripamil Test Dose Paroxysmal Supraventricular Tachycardia Phase 3 · NCT03464019 Terminated
Etripamil NS 70 mg Paroxysmal Supraventricular Tachycardia Phase 3 · NCT03635996 Terminated
Dalcetrapib Acute Coronary Syndrome Phase 3 · NCT02525939 Completed
Cefepime-zidebactam (FEP-ZID) Complicated Urinary Tract Infection Phase 3 · NCT04979806 Completed
Pritelivir (AIC316) HSV Infection Phase 3 · NCT03073967 Completed
Rugonersen Angelman Syndrome Phase 3 · NCT07605429 Recruiting
Sevasemten Becker Muscular Dystrophy Phase 2 · NCT06066580 Enrolling by invitation
Dapolsertib Acute Myeloid Leukemia Phase 1/2 · NCT03008187 Completed
Levosimendan Hypertension Pulmonary Secondary Heart Failure Phase 2 · NCT03624010 Completed
RAD101 (18F-FPIA) Brain Metastases From Solid Tumors Phase 2 · NCT06777433 Active not recruiting
Tomivosertib Non-small Cell Lung Cancer Phase 2 · NCT04622007 Unknown
ETC-1002 Hypercholesterolemia Phase 2 · NCT02178098 Completed

Also used in these trials (approved or third-party drugs, not MEDP's own candidates): Spinosad, Inclisiran, Etripamil, Meropenem, Pembrolizumab, Pemetrexed Disodium, Triamcinolone Acetonide Extended-Release Injectable, Valacyclovir, Supra-pharmacologic Dexamethasone Sodium Phosphate AVM0703, Avacopan, Toripalimab, Tocilizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

MEDP holds $705.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when MEDP files for a raise →

👥 Who Owns MEDP

Insiders 18.6% Institutions (977 holders) 81.4% Public and other holders 0%
HolderTypeShares% of sharesAs of
August J. Troendle
President & CEO, Director, 10% owner · +30,000 options
Insider 5,071,244 18.13% 2026-09-29
AQR Capital Management, LLC Institution (13G, 5%+) 1,396,654 4.99% 2026-09-30
Susan E Burwig
Exec. VP, Operations · +15,000 options
Insider 54,012 0.19% 2026-10-26
Brian T Carley
Director · +1,145 options
Insider 27,861 0.10% 2026-09-30
Stephen P Ewald
General Counsel & Corp. Secy. · +15,000 options
Insider 19,098 0.07% 2026-10-29
Kevin M. Brady
CFO & Treasurer · +3,403 options
Insider 12,830 0.05% 2026-08-20
Cornelius P. III McCarthy
Director · +1,138 options
Insider 12,303 0.04% 2026-09-30
Fred B Jr Davenport
Director · +1,110 options
Insider 5,798 0.02% 2026-08-19
Robert O. Kraft
Director · +1,142 options
Insider 987 0.00% 2026-09-30
Brad W. Hansman
Exec. VP, Operations
Insider 697 0.00% 2026-06-01

Share count 27,971,686 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full MEDP picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for MEDP and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.